



# Nanoform Finland Plc – Managers’ transactions – Johanna Kause

Company release

**Nanoform Finland Plc**

September 13, 2023

17:30 Finnish time / 16:30 Swedish time

## **Nanoform Finland Plc – Managers’ transactions – Johanna Kause**

[Helsinki, Finland](#) – Manager’s transaction related to Nanoform Finland Plc Chief Quality Officer Johanna Kause’s acceptance of stock options of Nanoform Finland Plc:

Nanoform Finland Oyj - Managers' Transactions

---

Person subject to the notification requirement

Name: Johanna Kause

Position: Other senior manager

Issuer: Nanoform Finland Oyj

LEI: 743700JJO2NU8LBS1592

Notification type: INITIAL NOTIFICATION

Reference number: 37719/5/4

---

Transaction date: 2023-09-13

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: Nanoform Finland Oyj stock option 1/2023

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

Linked to stock option programme

Transaction details

(1): Volume: 50000 Unit price: 0 EUR

Aggregated transactions (1):

Volume: 50000 Volume weighted average price: 0 EUR

For further information, please contact:

Peter Hänninen

General Counsel

[peter.hanninen@nanoform.com](mailto:peter.hanninen@nanoform.com)

+358 50 353 0408

For investor relations queries, please contact:

Henri von Haartman

Director of Investor Relations

[hvh@nanoform.com](mailto:hvh@nanoform.com)

+46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit [www.nanoform.com](http://www.nanoform.com).